Kari T. Kivistö

6.9k total citations
82 papers, 5.2k citations indexed

About

Kari T. Kivistö is a scholar working on Pharmacology, Pharmacology and Oncology. According to data from OpenAlex, Kari T. Kivistö has authored 82 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pharmacology, 27 papers in Pharmacology and 24 papers in Oncology. Recurrent topics in Kari T. Kivistö's work include Pharmacogenetics and Drug Metabolism (27 papers), Drug Transport and Resistance Mechanisms (20 papers) and Poisoning and overdose treatments (17 papers). Kari T. Kivistö is often cited by papers focused on Pharmacogenetics and Drug Metabolism (27 papers), Drug Transport and Resistance Mechanisms (20 papers) and Poisoning and overdose treatments (17 papers). Kari T. Kivistö collaborates with scholars based in Finland, Germany and Czechia. Kari T. Kivistö's co-authors include Pertti J. Neuvonen, Janne T. Backman, Teemu Kantola, Mikko Niemi, Martin F. Fromm, Michel Eichelbaum, Mikko Neuvonen, Taru Kantola, Klaus T. Olkkola and Tommi Lamberg and has published in prestigious journals such as Neurology, Antimicrobial Agents and Chemotherapy and Pharmaceutical Research.

In The Last Decade

Kari T. Kivistö

82 papers receiving 4.9k citations

Peers

Countries citing papers authored by Kari T. Kivistö

Since Specialization

Citations

This map shows the geographic impact of Kari T. Kivistö's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari T. Kivistö with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari T. Kivistö more than expected).

Fields of papers citing papers by Kari T. Kivistö

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari T. Kivistö. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari T. Kivistö. The network helps show where Kari T. Kivistö may publish in the future.

Co-authorship network of co-authors of Kari T. Kivistö

This figure shows the co-authorship network connecting the top 25 collaborators of Kari T. Kivistö. A scholar is included among the top collaborators of Kari T. Kivistö based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kari T. Kivistö. Kari T. Kivistö is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study 2006 ·European Journal of Clinical Pharmacology ·Dagmar Busse, (unknown), Gerd Mikus, Matthias Schwab, Ute Hofmann, Michel Eichelbaum, Kari T. Kivistö	19
2	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype 17 2005 ·Pharmacogenetics and Genomics* ·Mikko Niemi, Pertti J. Neuvonen, Ute Hofmann, Janne T. Backman, Matthias Schwab, Dieter Lütjohann, Klaus von Bergmann, Michel Eichelbaum, Kari T. Kivistö	95
3	Gastric decontamination performed 5 min after the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage 2000 ·British Journal of Clinical Pharmacology ·Outi Lapatto‐Reiniluoto, Kari T. Kivistö, Pertti J. Neuvonen	11
4	Identification of Drugs Ingested in Acute Poisoning: Correlation of Patient History With Drug Analyses 2000 ·Therapeutic Drug Monitoring ·Sinikka Pohjola‐Sintonen, Kari T. Kivistö, Erkki Vuori, Outi Lapatto‐Reiniluoto, E Tiula, Pertti J. Neuvonen	50
5	Grapefruit juice can increase the plasma concentrations of oral methylprednisolone 2000 ·European Journal of Clinical Pharmacology ·Tiina Varis, Kari T. Kivistö, Pertti J. Neuvonen	27
6	Effects of metronidazole on midazolam metabolism in vitro and in vivo 2000 ·European Journal of Clinical Pharmacology ·(unknown), Janne T. Backman, Kari T. Kivistö, Pertti J. Neuvonen	27
7	Involvement of CYP1A2 and CYP3A4 in Lidocaine N-Deethylation and 3-Hydroxylation in Humans 2000 ·Drug Metabolism and Disposition ·Junsheng Wang, Janne T. Backman, Päivi Taavitsainen, Pertti J. Neuvonen, Kari T. Kivistö	80
8	Quantitative immunohistochemical analysis of the glutathione S-transferase GSTM1: in situ phenotyping in archival material 1999 ·Xenobiotica ·Péter Fritz, Bernhard Sperker, Thomas E. Mürdter, M. Späth, Peter Schwarzmann, H K Kroemer, Michel Eichelbaum, Kari T. Kivistö	4
9	Effect of itraconazole on cerivastatin pharmacokinetics 1999 ·European Journal of Clinical Pharmacology ·Taru Kantola, Kari T. Kivistö, Pertti J. Neuvonen	34
10	The Effect of Dexamethasone on the Pharmacokinetics of Triazolam 1998 ·Pharmacology & Toxicology ·(unknown), Kari T. Kivistö, Pertti J. Neuvonen	38
11	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole* 1998 ·Clinical Pharmacology & Therapeutics ·Pertti J. Neuvonen, Teemu Kantola, Kari T. Kivistö	323
12	The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone 1998 ·European Journal of Clinical Pharmacology ·Tommi Lamberg, Kari T. Kivistö, Jouko Laitila, (unknown), Pertti J. Neuvonen	25
13	Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin 1998 ·British Journal of Clinical Pharmacology ·Kari T. Kivistö, Taru Kantola, Pertti J. Neuvonen	137
14	Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole* 1998 ·Clinical Pharmacology & Therapeutics ·Tiina Varis, Kirsi‐Maija Kaukonen, Kari T. Kivistö, Pertti J. Neuvonen	72
15	Triazolam is ineffective in patients taking rifampin 1997 ·Clinical Pharmacology & Therapeutics ·(unknown), Kari T. Kivistö, Janne T. Backman, Klaus T. Olkkola, Pertti J. Neuvonen	83
16	Rifampin reduces plasma concentrations and effects of zolpidem* 1997 ·Clinical Pharmacology & Therapeutics ·(unknown), Kari T. Kivistö, Harri Luurila, Pertti J. Neuvonen	53
17	The Effect of Activated Charcoal on the Absorption of Fluoxetine, with Special Reference to Delayed Charcoal Administration 1996 ·Pharmacology & Toxicology ·(unknown), Kari T. Kivistö, (unknown), Pertti J. Neuvonen	16
18	The Ex-Vivo Isolated, Perfused Human Lung Model: Description and Potential Applications 1996 ·The Thoracic and Cardiovascular Surgeon ·A. Linder, Godehard Friedel, Péter Fritz, Kari T. Kivistö, Monika McClellan, H. Toomes	28
19	Different effects of products containing metal ions on the absorption of lomefloxacin 1994 ·Clinical Pharmacology & Therapeutics ·(unknown), Kari T. Kivistö	8
20	A Review of Assay Methods for Cyclosporin 1992 ·Clinical Pharmacokinetics ·Kari T. Kivistö	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact